Cargando…
Mixed pathologies and neural reserve: Implications of complexity for Alzheimer disease drug discovery
In a Perspective, David Bennett makes a case for neural reserve to be considered as a therapeutic endpoint in clinical trials for dementia.
Autor principal: | Bennett, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349649/ https://www.ncbi.nlm.nih.gov/pubmed/28291788 http://dx.doi.org/10.1371/journal.pmed.1002256 |
Ejemplares similares
-
Open drug discovery in Alzheimer's disease
por: Axtman, Alison D., et al.
Publicado: (2023) -
Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development
por: Rabinovici, Gil D., et al.
Publicado: (2016) -
A perspective on multi-target drug discovery and design for complex diseases
por: Ramsay, Rona R., et al.
Publicado: (2018) -
Sex, ApoE4 and Alzheimer’s disease: rethinking drug discovery in the era of precision medicine
por: Paranjpe, Manish D., et al.
Publicado: (2021) -
TDP-43 and amyloid precursor protein processing: implications for Alzheimer’s disease
por: Hicks, David A.
Publicado: (2020)